Short acting beta agonist (SABA) inhalers do not possess any anti-inflammatory properties, yet they are the most widely prescribed inhaler treatment for asthma in the UK. SENTINEL Plus is a programme designed to improve outcomes for asthma patients through identifying and addressing SABA over-reliance.
This website is part of the SENTINEL Plus quality improvement package which has been funded by AstraZeneca and co-developed with Hull York Medical School and Hull University Teaching Hospitals NHS Trust.
This website is intended for UK Healthcare Professionals.
The content of this website is intended for UK Healthcare Professionals only and contains non-promotional content.